Triveni Doses First Subject in Global Phase 2 Proof of Concept Study of TRIV-509 in Atopic Dermatitis, Presents Translational Data at 2025 EADV Congress Demonstrating Novel Biology in Patient Samples

— Phase 2 atopic dermatitis (AD) study advances TRIV-509, a differentiated anti-KLK5/7 antibody with the potential to deliver a new level of clinical efficacy and a convenient quarterly subcutaneous dosing option — — Oral presentation at EADV Congress 2025 bridges preclinical and clinical findings in AD patient explants and further validates the novel KLK5/7 mechanism […] The post Triveni Doses First Subject in Global Phase 2 Proof of Concept Study of TRIV-509 in Atopic Dermatitis, Presents Translational Data at 2025 EADV Congress Demonstrating Novel Biology in Patient Samples appeared first o